News Releases
Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.
-
May 29, 2020XTANDI is now MHLW-approved for both metastatic hormone-sensitive prostate cancer and castration-resistant prostate cancer in Japan
-
May 20, 2020Submission for the treatment of anemia in adult patients with chronic kidney disease
-
Feb 19, 2020- Breakthrough Therapy Designation Based on Initial Results from Phase 1b/2 EV-103 Clinical Trial -
-
Feb 10, 2020- After Median Follow-Up of 11.5 Months, 73 Percent of Patients Had Confirmed Tumor Response with Majority of Responses Still Ongoing; No New Safety Signals Observed for the Combination - - Findings To Be Presented During an Oral Session at the 2020 Genitourinary Cancers Symposium -
-
Feb 10, 2020- New Funding will Address Disparities in Mental Health Diagnosis and Treatment for 400,000 People in Need -